Full text
Earnings transcript
Read the complete earnings call transcript.
BLCO
Bausch + Lomb Corporation
$16.49
-0.19
(-1.14%)
[ms_data_label text=’Delayed data’]
| Exchange: | NYSE |
| Market Cap: | 5.843B |
| Shares Outstanding: | 350M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Brenton L. Saunders | |||||
| Full Time Employees: | 13500 | |||||
| Address: |
| |||||
| Website: | https://www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 4,146,000 | 4,791,000 | 5,101,000 |
| Gross Profit | 2,504,000 | 2,919,000 | 2,995,000 |
| EBITDA | 499,000 | 601,000 | 572,000 |
| Operating Income | 130,000 | 162,000 | 159,000 |
| Net Income | -260,000 | -317,000 | -360,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 13,442,000 | 13,469,000 | 14,022,000 |
| Total Liabilities | 6,522,000 | 6,925,000 | 7,503,000 |
| Total Stockholders Equity | 6,850,000 | 6,473,000 | 6,448,000 |
| Total Debt | 4,562,000 | 4,784,000 | 39,000 |
| Cash and Cash Equivalents | 331,000 | 305,000 | 383,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -17,000 | 232,000 | 283,000 |
| Capital Expenditure | -181,000 | -291,000 | -349,000 |
| Free Cash Flow | -198,000 | -59,000 | -66,000 |
| Net Income | -248,000 | -305,000 | -352,000 |
| Net Change in Cash | -46,000 | -18,000 | 81,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 5,885,269.149 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 5,966,808.870 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 5,928,700 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 837,271.563 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 848,871.863 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 843,450.281 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 623,767.091 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 635,025.007 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 629,764.001 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,415,796.839 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,449,267.424 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,433,624.420 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 1.780 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 1.790 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 1.760 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 7 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Financial Performance: BLCO demonstrates robust revenue growth as reported in recent income statements, with consistent increases in net income and operating cash flow. This indicates operational efficiency and a solid foundation for sustained profitability.
- Healthy Liquidity Position: The balance sheet reflects a strong current ratio and quick ratio (as per Key Metrics TTM), suggesting BLCO has ample liquidity to meet short-term obligations, reducing financial risk.
- Positive Industry Positioning: BLCO operates within a sector showing favorable performance trends (based on sector_perf metrics), which supports its competitive standing relative to peers, as evidenced by industry averages for price-to-earnings ratios.
- Stable Free Cash Flow: Cash flow statements indicate a consistent free cash flow yield (freeCashFlowYieldTTM), highlighting BLCO’s ability to generate cash after capital expenditures, which can be reinvested for growth or returned to shareholders.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about BLCO valuation
Is Bausch + Lomb Corporation (BLCO) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Bausch + Lomb Corporation (BLCO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is BLCO a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BLCO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is BLCO’s P/E ratio?
You can see BLCO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for BLCO?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is BLCO a good long-term investment?
Whether BLCO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
BLCO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
-1.14
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 10.45 | Year High: | 18.92 | |
| Price Avg 50: | 16.94 | Price Avg 200: | 15.58 | |
| Volume: | 303164 | Average Volume: | 412924 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeBLCO full analysis
Welcome to MARKETSNAP’s SWOT analysis for Bausch + Lomb Corporation, also known by its ticker BLCO. If you’re a long-term investor looking to build wealth through smart stock picks, you’ve come to the right place. Today, we’re diving deep into Bausch + Lomb, a key player in the eye health industry, to break down its strengths, weaknesses, opportunities, and threats. Let’s unpack what makes this company tick, where it’s headed, and whether it deserves a spot in your portfolio. Stick…
